

## Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association

June 1, 2007 1:22 PM ET

SOUTH SAN FRANCISCO, Calif., June 1, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the company will present data from ongoing clinical studies of SNS-595 and SNS-032 at the 12th Congress of the European Hematology Association (EHA) being held June 7-10, 2007 in Vienna, Austria.

Presentations will include updated interim data from the company's Phase 1 clinical trial of SNS-595 in acute leukemias, as well as clinical data from an ongoing study of SNS-032 further detailing that compound's mechanism of action.

-- Abstract #0489: "Pharmacokinetic/Pharmacodynamic Correlation with Responses in a Phase 1 Study of Patients with Relapsed/Refractory Acute Leukemias Treated with SNS-595" will be presented on Saturday, June 9, 2007 from 6:00-7:15 p.m. during the Acute Myeloid Leukemia -- Clinical II poster session.

-- Abstract #0742: "SNS-032 Exhibits Dose-Dependent Mechanism-Based Inhibition of CDK7 and CDK9 in Peripheral Blood Mononuclear Cells from Patients with Advanced Cancers Treated in an Ongoing Phase 1 Trial" will be presented on Saturday, June 9, 2007 from 6:00-7:15 p.m. during the Novel Therapeutics and Targeted Therapies poster session.

### About Sunesis' Oncology Programs

Sunesis has built a rich portfolio of product candidates in oncology focused on novel pathways and targets, including inhibition of the cell-cycle and survival signaling. Sunesis is currently conducting Phase 2 clinical trials in lung and ovarian cancer and a Phase 1 clinical trial in acute leukemias for its lead compound, SNS-595. SNS-032, a selective inhibitor of cyclin-dependent kinases 7 and 9, is being evaluated in Phase 1 clinical trials in B-cell malignancies and in advanced solid tumors. The company's Aurora kinase inhibitor, SNS-314, is expected to begin Phase 1 clinical trials in the first half of 2007. In addition, Sunesis is developing novel small molecule inhibitors of Raf kinase and other oncology kinases in collaboration with Biogen Idec.

### About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit <http://www.sunesis.com>.

### Forward-Looking Statements

This press release may contain forward-looking statements that involve substantial risks and uncertainties. Sunesis may not actually achieve the plans, intentions or expectations contained in such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations contained in such forward-looking statements. Sunesis does not assume any obligation to update any such forward-looking statements. For further information on Sunesis Pharmaceuticals, please visit <http://www.sunesis.com>.

### SOURCE Sunesis Pharmaceuticals, Inc.

Investors, Eric Bjerkholt, SVP, Corporate Development & Finance of Sunesis Pharmaceuticals, Inc., +1-650-266-3717; or Karen L. Bergman, +1-650-575-1509, or

Michelle Corral, +1-415-794-8662, both of BCC Partners, for Sunesis Pharmaceuticals, Inc.

<http://www.sunesis.com>

Copyright (C) 2007 PR Newswire. All rights reserved

News Provided by COMTEX